Clinical Trials
BGB-16673 vs. Pirtobrutinib in patients w/relapsed/refractory CLL or SLL
Disease Type: Leukemia , Disease Type: Lymphoma
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville